Rocket Pharmaceuticals, Inc. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Rocket Pharmaceuticals, Inc. (RCKT) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 14.16 million shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2026-05-07
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2026-03-31 was 14.16M shares, a 17.67% decline year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-09-30 was 16.67M shares, a 3.24% increase year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-06-30 was 16.36M shares, a 1.59% increase year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2025-03-31 was 17.20M shares, a 8.02% increase year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2025 was 12.16M shares, a 24.19% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2024 was 16.04M shares, a 7.94% increase from fiscal 2023.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2023 was 14.86M shares, a 13.13% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2022 was 13.14M shares, a 17.90% increase from fiscal 2021.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | 14.16M shares 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | 12.16M shares 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | 16.67M shares 10-Q · filed 2025-11-06 | 16.67M shares 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 16.36M shares 10-Q · filed 2025-08-07 | 16.36M shares 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | 17.20M shares 10-Q · filed 2026-05-07 | |||||
| 2024-12-31 | 16.04M shares 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | 16.15M shares 10-Q · filed 2025-11-06 | 16.15M shares 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 16.11M shares 10-Q · filed 2025-08-07 | 16.11M shares 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 15.92M shares 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | 14.86M shares 10-K · filed 2025-02-27 | |||||
| 2023-09-30 | 14.89M shares 10-Q · filed 2024-11-07 | 14.89M shares 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | 14.88M shares 10-Q · filed 2023-08-09 | 14.88M shares 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | 14.65M shares 10-Q · filed 2024-05-07 | |||||
| 2022-12-31 | 13.14M shares 10-K · filed 2025-02-27 | |||||
| 2022-09-30 | 12.73M shares 10-Q · filed 2023-11-07 | 12.73M shares 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | 12.53M shares 10-Q · filed 2023-08-09 | 12.53M shares 10-Q · filed 2023-08-09 | ||||
| 2022-03-31 | 12.05M shares 10-Q · filed 2023-05-05 | |||||
| 2021-12-31 | 11.14M shares 10-K · filed 2024-02-27 | |||||
| 2021-09-30 | 11.04M shares 10-Q · filed 2022-11-04 | 11.11M shares 10-Q · filed 2021-11-05 | 11.04M shares 10-Q · filed 2022-11-04 | 11.11M shares 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | 11.04M shares 10-Q · filed 2022-08-09 | 11.04M shares 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 10.89M shares 10-Q · filed 2022-05-06 | |||||
| 2020-12-31 | 11.05M shares 10-K · filed 2023-02-28 | |||||
| 2020-09-30 | 10.92M shares 10-Q · filed 2021-11-05 | 10.92M shares 10-Q · filed 2021-11-05 | ||||
| 2020-06-30 | 10.78M shares 10-Q · filed 2021-08-09 | 10.78M shares 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | 10.54M shares 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | 9.61M shares 10-K · filed 2022-02-28 | |||||
| 2018-12-31 | 8.62M shares 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |